Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

lenta and TDCA, impaired colonic epithelium and increased activation of MAPK/ERK and proinflammatory pathways in recipient mice. Our findings indicate that cigarette smoking causes compositional ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...

Pfizer Inc. today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

The cerebral cortex is the seat of complex brain functions and is a highly organized and compartmentalized structure. Its development relies on several progenitor types. These cells have specific ...

inspired by the promise of targeting cancer-associated molecular pathways upstream of other targets like RAS/ERK MAPK, which drive cellular proliferation and survival. According to BridgeBio and ...

and RTK signaling pathways; small cell lung cancer: Cell cycle, Chromatin histone acetylation, Cytoskeleton, DNA replication, ERK MAPK signaling, Hormone-related, IGF1R signaling, JNK and p38 ...